A Study of MGC026 in Participants With Advanced Solid Tumors

NCT06242470 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Advanced Cancer
Metastatic Cancer
Squamous Cell Carcinoma of Head and Neck
Non Small Cell Lung Cancer
Small-cell Lung Cancer
Bladder Cancer
Sarcoma
Endometrial Cancer
Melanoma
Castration Resistant Prostatic Cancer
Cervical Cancer
Colorectal Cancer
Gastric Cancer
Gastro-esophageal Cancer
Pancreas Cancer
Clear Cell Renal Cell Carcinoma
Hepatocellular Carcinoma
Platinum-resistant Ovarian Cancer
Breast Cancer
Ovarian Cancer
Esophageal Squamous Cell Cancer (SCC)

Interventions

BIOLOGICAL: MGC026 Dose Escalation
BIOLOGICAL: MGC026 Dose for Expansion

Sponsor

MacroGenics